6.75
-0.19 (-2.67%)
| 前收盘价格 | 6.93 |
| 收盘价格 | 6.94 |
| 成交量 | 1,470,664 |
| 平均成交量 (3个月) | 4,965,793 |
| 市值 | 2,079,072,128 |
| 预期市盈率 (P/E Forward) | 17.06 |
| 价格/销量 (P/S) | 4.30 |
| 股市价格/股市净资产 (P/B) | 12.08 |
| 52周波幅 | |
| 利润日期 | 31 Jul 2025 |
| 营业毛利率 | -5.41% |
| 营业利益率 (TTM) | -6.35% |
| 稀释每股收益 (EPS TTM) | -0.090 |
| 季度收入增长率 (YOY) | 13.40% |
| 总债务/股东权益 (D/E MRQ) | 229.11% |
| 流动比率 (MRQ) | 3.34 |
| 营业现金流 (OCF TTM) | 3.56 M |
| 杠杆自由现金流 (LFCF TTM) | 29.27 M |
| 资产报酬率 (ROA TTM) | 3.95% |
| 股东权益报酬率 (ROE TTM) | -18.12% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Amicus Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 3.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.25 |
|
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.72% |
| 机构持股比例 | 103.25% |
| 52周波幅 | ||
| 中 | 108.00 (1,501.19%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Morgan Stanley | 17 Jul 2025 | 108.00 (1,501.19%) | 购买 | 6.29 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合